Artal Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Artal Group’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,000,000	Closed	-$7.77M	–	99
2023 Q3	$7.77M	Hold	1,000,000	–	–	0.33%	49
2023 Q2	$9.68M	Hold	1,000,000	–	–	0.3%	51
2023 Q1	$11M	Hold	1,000,000	–	–	0.65%	38
2022 Q4	$4.32M	Hold	1,000,000	–	–	0.24%	66
2022 Q3	$7.52M	Hold	1,000,000	–	–	0.32%	51
2022 Q2	$10.1M	Hold	1,000,000	–	–	0.54%	36
2022 Q1	$12.4M	Hold	1,000,000	–	–	0.52%	43
2021 Q4	$22.9M	Hold	1,000,000	–	–	0.62%	43
2021 Q3	$22.1M	Hold	1,000,000	–	–	0.5%	52
2021 Q2	$13M	Hold	1,000,000	–	–	0.26%	78
2021 Q1	$13M	Hold	1,000,000	–	–	0.23%	86
2020 Q4	$13.8M	Hold	1,000,000	–	–	0.3%	77
2020 Q3	$14.7M	Buy	1,000,000 +100,000	+11%	+$1.45M	0.36%	61
2020 Q2	$14.6M	Buy	900,000 +150,000	+20%	+$2.4M	0.41%	56
2020 Q1	$10.9M	Buy	+750,000	New	+$13.2M	0.46%	45

Other funds holding AUPH

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Artal Group's AUPH Position: Q4 2023 in Review

Artal Group sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2023, closing a stake of 1,000,000 shares — an estimated $7.77M sold.

Artal Group first reported a position in AUPH in Q1 2020 and held it in 15 quarters. The position peaked at $22.9M in Q4 2021. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2023.

Artal Group reported no remaining Aurinia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Artal Group sold 1,000,000 Aurinia Pharmaceuticals shares in Q4 2023, an estimated $7.77M.
Artal Group first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 15 quarters.
Artal Group's Aurinia Pharmaceuticals position peaked at $22.9M in Q4 2021.
191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.